For the quarter ending 2025-09-30, JAZZ made $1,126,107K in revenue. $251,412K in net income. Net profit margin of 22.33%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 1,126,107 | 1,045,712 | 897,841 | 1,054,969 |
| Cost of product sales (excluding amortization of acquired developed technologies) | 128,880 | 116,268 | 104,620 | 111,611 |
| Selling, general and administrative | 530,647 | 358,399 | 514,013 | 325,772 |
| Research and development | 198,203 | 189,972 | 180,652 | 199,919 |
| Intangible asset amortization | 168,368 | 162,103 | 154,448 | 157,457 |
| Acquired in-process research and development | 42,500 | 905,362 | - | - |
| Total operating expenses | 1,068,598 | 1,732,104 | 953,733 | 794,759 |
| Income (loss) from operations | 57,509 | -686,392 | -55,892 | 260,210 |
| Interest expense, net | -48,576 | -47,363 | -53,706 | -58,702 |
| Foreign exchange gain (loss) | 102 | -1,799 | -213 | -701 |
| Income (loss) before income tax benefit and equity in loss of investees | 9,035 | -735,554 | -109,811 | 200,807 |
| Income tax benefit | -242,424 | -17,170 | -17,812 | -14,533 |
| Equity in loss of investees | -47 | -86 | -542 | -285 |
| Net income (loss) | 251,412 | -718,470 | -92,541 | 215,055 |
| Basic (in dollars per share) | 4.14 | -11.74 | -1.52 | 3.5 |
| Diluted (in dollars per share) | 4.08 | -11.74 | -1.52 | 3.42 |
| Weighted-average ordinary shares used in per share calculations - basic (in shares) | 60,696,000 | 61,194,000 | 60,979,000 | 61,414,000 |
| Weighted-average ordinary shares used in per share calculations - diluted (in shares) | 61,606,000 | 61,194,000 | 60,979,000 | 63,174,000 |
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)